Xencor (XNCR) Total Current Liabilities (2013 - 2026)
Xencor (XNCR) reported Total Current Liabilities of $73.5 million for Q1 2026, down 16.94% year-over-year from $88.4 million in Q1 2025, and down 23.41% quarter-over-quarter from $95.9 million in Q4 2025.
Xencor (XNCR) Total Current Liabilities (2013 - 2026) Analysis & Trends
Xencor (XNCR) has 14 years of Total Current Liabilities data on file, last reported at $73.5 million in Q1 2026.
- Total Current Liabilities for Q1 2026 came in at $73.5 million, down 16.94% year-over-year; the trailing twelve-month figure through Mar 2026 was $73.5 million (down 16.94% YoY), and the FY2025 annual result was $95.9 million, up 9.69% from the prior year.
- Total Current Liabilities retreated to $73.5 million in Q1 2026 per XNCR's latest filing, from $95.9 million in the prior quarter.
- Over five years, Total Current Liabilities peaked at $96.1 million in Q2 2025 and troughed at $44.6 million in Q2 2023.
- A 5-year average of $76.0 million and a median of $75.0 million in 2022 frame the typical range for Total Current Liabilities.
- The sharpest annual moves came in 2022 and 2023: Total Current Liabilities soared 103.15% in 2022, then slumped 41.09% in 2023.
- A 5-year view of Total Current Liabilities shows it stood at $63.8 million in 2022, then gained by 15.77% to $73.9 million in 2023, then gained by 18.29% to $87.4 million in 2024, then gained by 9.69% to $95.9 million in 2025, then slipped by 23.41% to $73.5 million in 2026.
- Business Quant data shows XNCR's Total Current Liabilities at $73.5 million in Q1 2026, $95.9 million in Q4 2025, and $86.5 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 1.70 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 16.35 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 636.40 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 13.42 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 3.88 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 72.86 Mn |
| 10 | Xencor | 953.38 Mn | 878.64 Mn | - | 73.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 73.46 Mn |
| Dec 31, 2025 | 95.91 Mn |
| Sep 30, 2025 | 86.49 Mn |
| Jun 30, 2025 | 96.08 Mn |
| Mar 31, 2025 | 88.44 Mn |
| Dec 31, 2024 | 87.43 Mn |
| Sep 30, 2024 | 90.81 Mn |
| Jun 30, 2024 | 75.59 Mn |
| Mar 31, 2024 | 71.08 Mn |
| Dec 31, 2023 | 73.92 Mn |
| Sep 30, 2023 | 53.04 Mn |
| Jun 30, 2023 | 44.63 Mn |
| Mar 31, 2023 | 65.06 Mn |
| Dec 31, 2022 | 63.84 Mn |
| Sep 30, 2022 | 90.03 Mn |
| Jun 30, 2022 | 75.04 Mn |
| Mar 31, 2022 | 60.94 Mn |
| Dec 31, 2021 | 70.74 Mn |
| Sep 30, 2021 | 44.32 Mn |
| Jun 30, 2021 | 45.96 Mn |